<p>瑞金製藥（NASDAQ:REGN - 獲取免費報告）在週六發佈的研究報告中被華爾街 Zen 的股票研究人員從 “買入” 評級下調至 “持有” 評級。</p>
<ul>
<li>輝瑞加大對減肥藥物的投資</li>
</ul>
<p>其他幾位股票研究分析師也對該公司發表了看法。滙豐全球研究在 11 月 24 日的研究報告中將瑞金製藥的評級上調至 “強力買入”。古根海姆在 10 月 29 日的研究報告中將瑞金製藥的目標價從 815.00 美元上調至 865.00 美元，並給予該公司 “買入” 評級。滙豐在 11 月 24 日的報告中開始覆蓋瑞金製藥的股票，設定了 “買入” 評級和 255.00 美元的目標價。BMO 資本市場在 12 月 4 日的研究報告中將瑞金製藥的目標價從 725.00 美元上調至 850.00 美元，並給予該股票 “跑贏大盤” 評級。最後，加拿大皇家銀行在 10 月 29 日的研究報告中將瑞金製藥的目標價從 704.00 美元上調至 708.00 美元，並給予該股票 “行業表現” 評級。三位投資分析師給予該股票 “強力買入” 評級，十五位給予 “買入” 評級，八位給予 “持有” 評級，一位給予 “賣出” 評級。根據 MarketBeat 的數據，瑞金製藥的平均評級為 “適度買入”，共識目標價為 779.45 美元。</p>
<p><strong>閲讀我們關於 REGN 的最新股票報告</strong></p>
<h2>瑞金製藥的價格表現</h2>
<ul>
<li>5 個醫療保健股票值得關注，因為行業輪換正在全面展開</li>
</ul>
<p>NASDAQ REGN 的股票在週五以 767.96 美元開盤。瑞金製藥的 1 年低點為 476.49 美元，1 年高點為 790.98 美元。該股票的市值為 807.1 億美元，市盈率為 18.39，市盈率/增長比率為 2.15，貝塔值為 0.37。公司的 50 日移動平均線為 682.40 美元，200 日移動平均線為 599.63 美元。公司的債務與股本比率為 0.09，流動比率為 4.06，速動比率為 3.33。</p>
<p>瑞金製藥（NASDAQ:REGN - 獲取免費報告）最近在 10 月 28 日發佈了季度財報。這家生物製藥公司報告本季度每股收益為 11.83 美元，超出共識預期的 9.73 美元，超出幅度為 2.10 美元。瑞金製藥的淨利潤率為 32.13%，股本回報率為 13.76%。該公司在本季度的收入為 37.5 億美元，而分析師預期為 35.7 億美元。去年同期，該公司每股收益為 12.46 美元。瑞金製藥的季度收入較去年同期增長了 0.9%。平均而言，賣方分析師預計瑞金製藥在當前年度的每股收益將達到 35.92 美元。</p>
<h2>內部人士下注</h2>
<ul>
<li>大跌者：3 只接近 1 年低點的股票，可能在 2025 年大幅上漲</li>
</ul>
<p>在其他瑞金製藥的新聞中，副總裁 Jason Pitofsky 在 11 月 7 日的交易中出售了 431 股公司的股票。該股票以平均 651.43 美元的價格出售，總價值為 280,766.33 美元。出售完成後，副總裁持有公司 4,233 股，價值 2,757,503.19 美元。這代表其持股減少了 9.24%。該交易在向 SEC 提交的文件中披露，文件可通過此超鏈接獲取。此外，董事 Christine A. Poon 在 10 月 29 日的交易中出售了 6,500 股公司的股票。該股票以平均 654.27 美元的價格出售，總交易額為 4,252,755.00 美元。出售後，董事持有公司 2,352 股，價值約 1,538,843.04 美元。該交易使其持股減少了 73.43%。該交易的披露在 SEC 文件中可獲得。目前，7.02% 的股票由公司內部人士持有。</p>
<h2>機構資金流入和流出</h2>
<p>最近幾家對沖基金和其他機構投資者增加或減少了對該公司的持股。Keel Point LLC 在第三季度購買了瑞金製藥的新股份，價值約 251,000 美元。CTC 替代策略有限公司在第三季度購買了瑞金製藥的新股份，價值 307,000 美元。Allworth Financial LP 在第三季度將其在瑞金製藥的持股增加了 50.5%。Allworth Financial LP 現在擁有 1,496 股生物製藥公司的股票，價值 841,000 美元，此前在上個季度購買了 502 股。IFP Advisors Inc 在第三季度將其在瑞金製藥的持股增加了 14.2%。IFP Advisors Inc 現在擁有 1,405 股生物製藥公司的股票，價值 790,000 美元，此前在上個季度購買了 175 股。最後，瑞士人壽資產管理有限公司在第三季度將其在瑞金製藥的持股增加了 112.0%。瑞士人壽資產管理有限公司現在擁有 23,658 股生物製藥公司的股票，價值 13,302,000 美元，此前在上個季度購買了 12,500 股。目前，83.31% 的股票由機構投資者持有。</p>
<h2>關於瑞金製藥</h2>
<p>（獲取免費報告）</p>
<p>瑞金製藥公司（NASDAQ: REGN）是一家總部位於美國的生物技術公司，成立於 1988 年，總部位於紐約州塔裏敦。該公司專注於發現、開發、生產和商業化用於治療嚴重醫療條件的藥物。公司結合實驗室研究、臨牀開發和內部生產，推進多個治療領域的生物治療管線。</p>
<p>瑞金以其專有的藥物發現技術而聞名，包括其 VelocImmune 平台，該平台用於生成完全人源的單克隆抗體。</p>
<h2>相關文章</h2>
<ul>
<li>我們更看好的五隻股票，勝過再生元製藥</li>
<li>股票情緒分析：它是如何運作的</li>
<li>耐克盈利超預期，但在中國市場面臨挑戰並遭遇關税</li>
<li>初學者如何閲讀股票圖表</li>
<li>人工智能熱潮是泡沫嗎？這兩隻分紅股票表示不是</li>
<li>內幕交易 - 你需要知道的事項</li>
<li>2026 年四隻高潛力 ETF：小型股、太空股票等</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkVHTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkVHTg"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1000 美元在再生元製藥嗎？</h2>
<p>在考慮再生元製藥之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而再生元製藥並不在名單上。</p>
<p>雖然再生元製藥目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

再生元制藥

<p>華爾街禪將再生元製藥的評級從 “買入” 下調至 “持有”。其他分析師的意見各異，有的將評級上調至 “強烈買入”，而有的則調整了目標價格。該股票的共識評級為 “適度買入”，目標價格為 779.45 美元。近期的內部交易和機構投資也受到關注</p>

<p>Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) was downgraded by equities researchers at Wall Street Zen from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research report issued on Saturday.</p>
<div class="lb-trans"><p>瑞金製藥（NASDAQ:REGN - 獲取免費報告）在週六發佈的研究報告中被華爾街 Zen 的股票研究人員從 “買入” 評級下調至 “持有” 評級。</p>
</div><ul>
<li>Pfizer Adds to Its Big Bet on Weight Loss Drugs</li>
</ul>
<div class="lb-trans"><ul>
<li>輝瑞加大對減肥藥物的投資</li>
</ul>
</div><p>Several other equities research analysts have also weighed in on the company. Hsbc Global Res upgraded Regeneron Pharmaceuticals to a &#34;strong-buy&#34; rating in a research report on Monday, November 24th. Guggenheim raised their price objective on Regeneron Pharmaceuticals from $815.00 to $865.00 and gave the company a &#34;buy&#34; rating in a research report on Wednesday, October 29th. HSBC began coverage on shares of Regeneron Pharmaceuticals in a report on Monday, November 24th. They set a &#34;buy&#34; rating and a $255.00 target price on the stock. BMO Capital Markets increased their price target on shares of Regeneron Pharmaceuticals from $725.00 to $850.00 and gave the stock an &#34;outperform&#34; rating in a research note on Thursday, December 4th. Finally, Royal Bank Of Canada boosted their price objective on shares of Regeneron Pharmaceuticals from $704.00 to $708.00 and gave the stock a &#34;sector perform&#34; rating in a research note on Wednesday, October 29th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Regeneron Pharmaceuticals has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $779.45.</p>
<div class="lb-trans"><p>其他幾位股票研究分析師也對該公司發表了看法。滙豐全球研究在 11 月 24 日的研究報告中將瑞金製藥的評級上調至 “強力買入”。古根海姆在 10 月 29 日的研究報告中將瑞金製藥的目標價從 815.00 美元上調至 865.00 美元，並給予該公司 “買入” 評級。滙豐在 11 月 24 日的報告中開始覆蓋瑞金製藥的股票，設定了 “買入” 評級和 255.00 美元的目標價。BMO 資本市場在 12 月 4 日的研究報告中將瑞金製藥的目標價從 725.00 美元上調至 850.00 美元，並給予該股票 “跑贏大盤” 評級。最後，加拿大皇家銀行在 10 月 29 日的研究報告中將瑞金製藥的目標價從 704.00 美元上調至 708.00 美元，並給予該股票 “行業表現” 評級。三位投資分析師給予該股票 “強力買入” 評級，十五位給予 “買入” 評級，八位給予 “持有” 評級，一位給予 “賣出” 評級。根據 MarketBeat 的數據，瑞金製藥的平均評級為 “適度買入”，共識目標價為 779.45 美元。</p>
</div><p><strong>Read Our Latest Stock Report on REGN</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 REGN 的最新股票報告</strong></p>
</div><h2>Regeneron Pharmaceuticals Price Performance</h2>
<div class="lb-trans"><h2>瑞金製藥的價格表現</h2>
</div><ul>
<li>5 Healthcare Names to Watch as Sector Rotation Is in Full Swing</li>
</ul>
<div class="lb-trans"><ul>
<li>5 個醫療保健股票值得關注，因為行業輪換正在全面展開</li>
</ul>
</div><p>Shares of NASDAQ REGN opened at $767.96 on Friday. Regeneron Pharmaceuticals has a 1 year low of $476.49 and a 1 year high of $790.98. The stock has a market capitalization of $80.71 billion, a P/E ratio of 18.39, a P/E/G ratio of 2.15 and a beta of 0.37. The company's 50-day moving average is $682.40 and its 200 day moving average is $599.63. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.06 and a quick ratio of 3.33.</p>
<div class="lb-trans"><p>NASDAQ REGN 的股票在週五以 767.96 美元開盤。瑞金製藥的 1 年低點為 476.49 美元，1 年高點為 790.98 美元。該股票的市值為 807.1 億美元，市盈率為 18.39，市盈率/增長比率為 2.15，貝塔值為 0.37。公司的 50 日移動平均線為 682.40 美元，200 日移動平均線為 599.63 美元。公司的債務與股本比率為 0.09，流動比率為 4.06，速動比率為 3.33。</p>
</div><p>Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $11.83 EPS for the quarter, topping the consensus estimate of $9.73 by $2.10. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The business had revenue of $3.75 billion during the quarter, compared to analyst estimates of $3.57 billion. During the same period last year, the business posted $12.46 earnings per share. Regeneron Pharmaceuticals's quarterly revenue was up .9% compared to the same quarter last year. On average, sell-side analysts expect that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current year.</p>
<div class="lb-trans"><p>瑞金製藥（NASDAQ:REGN - 獲取免費報告）最近在 10 月 28 日發佈了季度財報。這家生物製藥公司報告本季度每股收益為 11.83 美元，超出共識預期的 9.73 美元，超出幅度為 2.10 美元。瑞金製藥的淨利潤率為 32.13%，股本回報率為 13.76%。該公司在本季度的收入為 37.5 億美元，而分析師預期為 35.7 億美元。去年同期，該公司每股收益為 12.46 美元。瑞金製藥的季度收入較去年同期增長了 0.9%。平均而言，賣方分析師預計瑞金製藥在當前年度的每股收益將達到 35.92 美元。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>內部人士下注</h2>
</div><ul>
<li>Big Dippers: 3 Stocks Near 1-Year Lows That Could Surge in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>大跌者：3 只接近 1 年低點的股票，可能在 2025 年大幅上漲</li>
</ul>
</div><p>In other Regeneron Pharmaceuticals news, VP Jason Pitofsky sold 431 shares of the company's stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $651.43, for a total value of $280,766.33. Following the completion of the sale, the vice president owned 4,233 shares in the company, valued at $2,757,503.19. This represents a 9.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Christine A. Poon sold 6,500 shares of the firm's stock in a transaction that occurred on Wednesday, October 29th. The stock was sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the sale, the director owned 2,352 shares in the company, valued at approximately $1,538,843.04. The trade was a 73.43% decrease in their position. The disclosure for this sale is available in the SEC filing. 7.02% of the stock is currently owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他瑞金製藥的新聞中，副總裁 Jason Pitofsky 在 11 月 7 日的交易中出售了 431 股公司的股票。該股票以平均 651.43 美元的價格出售，總價值為 280,766.33 美元。出售完成後，副總裁持有公司 4,233 股，價值 2,757,503.19 美元。這代表其持股減少了 9.24%。該交易在向 SEC 提交的文件中披露，文件可通過此超鏈接獲取。此外，董事 Christine A. Poon 在 10 月 29 日的交易中出售了 6,500 股公司的股票。該股票以平均 654.27 美元的價格出售，總交易額為 4,252,755.00 美元。出售後，董事持有公司 2,352 股，價值約 1,538,843.04 美元。該交易使其持股減少了 73.43%。該交易的披露在 SEC 文件中可獲得。目前，7.02% 的股票由公司內部人士持有。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Keel Point LLC bought a new stake in shares of Regeneron Pharmaceuticals during the third quarter valued at approximately $251,000. CTC Alternative Strategies Ltd. bought a new stake in Regeneron Pharmaceuticals in the 3rd quarter valued at $307,000. Allworth Financial LP lifted its stake in Regeneron Pharmaceuticals by 50.5% in the 3rd quarter. Allworth Financial LP now owns 1,496 shares of the biopharmaceutical company's stock worth $841,000 after purchasing an additional 502 shares in the last quarter. IFP Advisors Inc boosted its holdings in shares of Regeneron Pharmaceuticals by 14.2% during the 3rd quarter. IFP Advisors Inc now owns 1,405 shares of the biopharmaceutical company's stock valued at $790,000 after purchasing an additional 175 shares during the last quarter. Finally, Swiss Life Asset Management Ltd grew its position in shares of Regeneron Pharmaceuticals by 112.0% during the third quarter. Swiss Life Asset Management Ltd now owns 23,658 shares of the biopharmaceutical company's stock valued at $13,302,000 after purchasing an additional 12,500 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>最近幾家對沖基金和其他機構投資者增加或減少了對該公司的持股。Keel Point LLC 在第三季度購買了瑞金製藥的新股份，價值約 251,000 美元。CTC 替代策略有限公司在第三季度購買了瑞金製藥的新股份，價值 307,000 美元。Allworth Financial LP 在第三季度將其在瑞金製藥的持股增加了 50.5%。Allworth Financial LP 現在擁有 1,496 股生物製藥公司的股票，價值 841,000 美元，此前在上個季度購買了 502 股。IFP Advisors Inc 在第三季度將其在瑞金製藥的持股增加了 14.2%。IFP Advisors Inc 現在擁有 1,405 股生物製藥公司的股票，價值 790,000 美元，此前在上個季度購買了 175 股。最後，瑞士人壽資產管理有限公司在第三季度將其在瑞金製藥的持股增加了 112.0%。瑞士人壽資產管理有限公司現在擁有 23,658 股生物製藥公司的股票，價值 13,302,000 美元，此前在上個季度購買了 12,500 股。目前，83.31% 的股票由機構投資者持有。</p>
</div><h2>About Regeneron Pharmaceuticals</h2>
<div class="lb-trans"><h2>關於瑞金製藥</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.</p>
<div class="lb-trans"><p>瑞金製藥公司（NASDAQ: REGN）是一家總部位於美國的生物技術公司，成立於 1988 年，總部位於紐約州塔裏敦。該公司專注於發現、開發、生產和商業化用於治療嚴重醫療條件的藥物。公司結合實驗室研究、臨牀開發和內部生產，推進多個治療領域的生物治療管線。</p>
</div><p>Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.</p>
<div class="lb-trans"><p>瑞金以其專有的藥物發現技術而聞名，包括其 VelocImmune 平台，該平台用於生成完全人源的單克隆抗體。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>相關文章</h2>
</div><ul>
<li>Five stocks we like better than Regeneron Pharmaceuticals</li>
<li>Stock Sentiment Analysis: How it Works</li>
<li>Nike Beats on Earnings But Struggles in China and Faces Tariffs</li>
<li>How to Read Stock Charts for Beginners</li>
<li>Is the AI Boom a Bubble? These 2 Dividend Stocks Say No</li>
<li>Insider Trading - What You Need to Know</li>
<li>4 High-Potential ETFs for 2026: Small Caps, Space Stocks, and More</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過再生元製藥</li>
<li>股票情緒分析：它是如何運作的</li>
<li>耐克盈利超預期，但在中國市場面臨挑戰並遭遇關税</li>
<li>初學者如何閲讀股票圖表</li>
<li>人工智能熱潮是泡沫嗎？這兩隻分紅股票表示不是</li>
<li>內幕交易 - 你需要知道的事項</li>
<li>2026 年四隻高潛力 ETF：小型股、太空股票等</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkVHTg" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=REGN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Regeneron Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在再生元製藥嗎？</h2>
</div><p>Before you consider Regeneron Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮再生元製藥之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regeneron Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而再生元製藥並不在名單上。</p>
</div><p>While Regeneron Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然再生元製藥目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

再生元製藥（NASDAQ:REGN）被華爾街 Zen 下調至持有評級